

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09664444	
	Filing Date		2000-09-18	
	First Named Inventor	Bell		
	Art Unit	1645		
	Examiner Name	R. Zeman		
	Attorney Docket Number	18003		

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20040170607		2004-09-02	Bell, John C. et al.	
	2	20030165465		2003-09-04	Roberts, Michael S. et al.	
	3	20030044384		2003-03-06	Roberts, Michael S. et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²ⁱ	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09664444
Filing Date		2000-09-18
First Named Inventor	Bell	
Art Unit	1645	
Examiner Name	R. Zeman	
Attorney Docket Number	18003	

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	BARBER, VSV-tumor selective replication and protein translation, Oncogene (2005) 24, 7710-7719	<input type="checkbox"/>
	2	CE'SAIRE et al., Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia, Oncogene (2006) 25, 349-358	<input type="checkbox"/>
	3	GARBER, China Approves World's First Oncolytic Virus Therapy For Cancer Treatment, Journal of the National Cancer Institute, Vol. 98, No. 5:298-300 (2006)	<input type="checkbox"/>
	4	LICHTY, Vesicular Stomatitis Virus: A Potential Therapeutic Virus for the Treatment of Hematologic Malignancy, Human Gene Therapy 15:821-831 (2004)	<input type="checkbox"/>
	5	NEMUNAITIS, Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer, Journal of Clinical Oncology, Vol 19, No 2 (January 2001): pp 289-298	<input type="checkbox"/>
	6	OBUCHI, Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity, Journal of Virology, (2003), p. 8843-8856	<input type="checkbox"/>
	7	PECORA, Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers, Journal of Clinical Oncology, Vol 20, No 9 (2002): pp 2251-2266	<input type="checkbox"/>
	8	POROSNICU, The Oncolytic Effect of Recombinant Vesicular Stomatitis Virus Is Enhanced by Expression of the Fusion Cytosine Deaminase/Uracil Phosphoribosyltransferase Suicide Gene, Cancer Research, 63, 8366-8376, (2003)	<input type="checkbox"/>
	9	STOJDL, VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents, Cancer Research 4:263-275 (2003)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09664444
Filing Date	2000-09-18
First Named Inventor	Bell
Art Unit	1645
Examiner Name	R. Zeman
Attorney Docket Number	18003

10		<input type="checkbox"/>
----	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09664444
Filing Date	2000-09-18
First Named Inventor	Bell
Art Unit	1645
Examiner Name	R. Zeman
Attorney Docket Number	18003

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☒ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Douglas A. Golightly/	Date (YYYY-MM-DD)	2007-08-02
Name/Print	Douglas A. Golightly	Registration Number	51,244

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**